![Sylvain Celanire](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Sylvain Celanire
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Augustine Therapeutics NV
![]() Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Direktor/Vorstandsmitglied | 01.08.2020 | - |
Vorstandsvorsitzender | 01.08.2020 | - |
Karriereverlauf von Sylvain Celanire
Statistik
International
Belgien | 2 |
Operativ
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Sektoral
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Augustine Therapeutics NV
![]() Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Health Services |
- Börse
- Insiders
- Sylvain Celanire
- Erfahrung